Main Article Content
Background: COVID -19 is a great threat to the human health worldwide and injury to the lungs is the main outcome of COVID-19 infection. In this context, it is believed that clinical -radiological findings along with biochemical alteration play a crucial role in diagnosis of disease. Aim: The aim of the present study was to ascertain the association of serum IL-6 levels with severity of lung injury in COVID-19 patients. Methodology: 130 patients of COVID-19 (93 males and 37 females) were included in this study and classified as mild, moderate and severe according to the revised guidelines on clinical management of COVID-19. Radiological findings in terms of high resolution computed tomography (CT) scan chest had been performed in only those COVID-19 patients in whom IL-6 test have been done. The collected data were analyzed statistically using standard methods and were compared by using Pearson correlation coefficient and Analysis of variance. Result: Marked elevated levels of serum IL6 were observed in COVID-19 patients and these levels showed a highly significant correlation (p-value < 0.001) with disease severity as characterized by raised CT score. In addition, serum IL-6 levels were negative correlated with SpO2 status in COVID-19 patients (r= -0.021; p<0.001) which reflect the need of intensive treatment of COVID-19 patients with very high IL-6 levels. Conclusion: Regular monitoring of IL-6 levels plays a crucial role in accessing the disease severity. Furthermore, these findings may help the clinicians to better understand the role of IL-6 in COVID -19 associated lung injury and also plan the therapeutic management of these patients, and thus, reducing the mortality of this global pandemic.
Prasad RS, Dixit R, Saxena R, Saxena S, Dimri P. Deteriorative effect of COVID 19 on digestive system of humans. In: Saxena R, Shaida B and Lukose S eds. COVID-19: A deteriorative conunderum of human health. 1st ed. New Delhi: Selective and Scientific Book publications, 2022, pp 162-166.
Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020; 50(4):382-383.
Liu Z, Li J, Chen D, Gao R, Zeng W, Chen S. et al. Dynamic Interleukin-6 level changes as a prognostic indicator in patients with COVID-19. Front Pharmacol. 2020;11:1093-1104.
Revised Guidelines on clinical management of COVID-19. Government of India, Ministry of Health & Family Welfare, Directorate General of Health Services (EMR Division) March 2020: pp 2-3.
Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. European radiology. 2020; 30(12): 6808-6817.
Sharma A, Tewari S, Deb MK, Marty JL. Severe acute respiratory syndrome corona virus 2 (SARS CoV 2 ) : A global pandemic and treatment strategies. Int J Antimicrobial Agents 2020; 56 (2): 106054-106067.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease. J Clin Invest. 2020; 130(5): 2620-2629.
Rosenbaum, L. Facing COVID-19in Italy- ethics, logistics and therapeutics on the epidemics front line. N Engl J Med 2020; 382:1873-1875.
Tanne JH. COVID-19: New York city deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020; 369: m1333.
Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020;50(4):382-383.
Bhandari S, Rankawat G, Singh A, Wadhwani D, Patel B. Evaluation of Interleukin-6 and its association with the severity of disease in COVID-19patients. Indian J Med Spec 2020; 11(3): 132-136.
Vatansever H S, Becer E. Relationship between IL-6 and COVID-19: to be considered during treatment. Future Virol 2021; 15(12): 817–822.